Oncology Antibody Candidates
Trellis’ cancer monoclonal antibodies follow in the footsteps of recent
scientific advances made towards targeted approaches against tumors, via antibodies targeting well-characterized
tumor-associated antigens and immune checkpoint modulators. Trellis is the first company to characterize anti-ICM antibodies
naturally present in healthy immune systems.
The first of our cancer therapeutics will reach Phase I clinical trials by 2018.
Immune Checkpoint Modulators (ICMs) and Tumor-Associated Antigens (TAAs)
Cancer is the second most common cause of death in the United States, accounting for nearly 1 in 4 deaths, 595,000 deaths estimated in 2016 (American Cancer Society).
Most Lethal Types:
- Lung and bronchial
- Liver and intrahepatic bile duct
Trellis antibodies fight cancer through two methods:
Immune Checkpoint Modulators (ICMs)
CellSpot identified optimal mAb, TRL8605 (green curve),
with greatest binding affinity to KIR2DL3 extracellular domain.
Tumor-Associated Antigens (TAAs)
In vitro pulse-chase experiment:
Trellis anti-ALK mAb, TRL10001, bound to ALK-expressing cells and was internalized within 30 minutes.
Frequencies of memory B-cells specific for ICMs are very low (single digits per 105 B-cells) but Trellis has found and cloned high affinity antibodies to several ICMs: KIR, TIM-3 B7-H3, LAG-3 and CEACAM1: